tbuckley/cabot-search huggingface dataset:
Abstract 3977: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells
Authors: Päivi Östling, Suvi-Katri Leivonen, Anna Aakula, Pekka Kohonen, Rami Mäkelä, Zandra Hagman, Anders Edsjö, Sara Kangaspeska, Henrik Edgren, Daniel Nicorici, Anders Bjartell, Yvonne Ceder, Merja Perälä, Olli Kallioniemi
Journal: Cancer Research (2011)

Abstract Androgen receptor (AR) is expressed in all stages of prostate cancer progression and its levels increase in the castration-resistant tumors. However, the mechanisms regulating AR expression remain poorly understood. Here, our aim was to determine the role of miRNAs in regulating AR protein. To this end, we performed a systematic gain-of function screen for 1129 miRNA molecules in prostate cancer cell lines and quantified changes in AR protein content using protein lysate microarrays. We identified 71 unique miRNAs that influenced the level of AR in LNCaP, LAPC-4, 22Rv1, CWR-1R and MDA-PCa-2B cells. Our RNA-sequencing data showed that the 3’UTRs of many genes, including the AR, are much longer than currently used by target prediction programs. Our analyses predicted that the majority of the miRNA regulation of AR would occur through the extended 6 kb 3’UTR. 3’UTR-binding assays validated 13 miRNAs (miR-135b, miR-185, miR-297, miR-299-3p, miR-34a, miR-34c, miR-371-3p, miR-421, miR-449a, miR-449b, miR-634, miR-654-5p, and miR-9) as direct AR regulators. Fifteen AR down-regulating miRNAs decreased androgen-induced proliferation of prostate cancer cells in vitro. Negative correlation of miR-34a and miR-34c expression with AR levels was also found in clinical prostate cancers. To conclude, our results demonstrate that miRNAs interacting with the long 3’UTR of the AR gene are important regulators of AR protein levels. This could be applied for developing novel therapeutic strategies to inhibit AR function and androgen-dependent cell growth. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3977. doi:10.1158/1538-7445.AM2011-3977
Case 26-1997
Authors: Joseph H. Friedman, M. Joe Ma
Journal: New England Journal of Medicine (1997)

Presentation of CaseA 64-year-old man was admitted to the Memory Disorders Clinic because of progressive dementia, seizures, and an unstable gait.Nine years before admission he was noted to repeat questions after having received the answers. Five years later he had a grand mal seizure, and treatment with phenytoin sodium was begun. One year before admission, electroconvulsive therapy was administered for severe depression. His gait became unsteady, and he fell three or four times daily, usually backward. His movements slowed, and he dragged his right leg while walking. He expressed fear that someone was going to break into his . . .
Abstract P4-03-01: Distance of breast cancer from the skin influence axillary nodal metastasis
Authors: EJ Kim, BJ Chae, BJ Song, HY Kwak, EY Chang, SH Kim, SS Jung
Journal: Cancer Research (2012)

Abstract Background: In breast cancer, axillary lymph node status is one of the most important prognostic variables and a crucial component to the staging system. Moreover, cancers underlying skin are willing to access to the lymphatics and cause lymphatic dissemination. Therefore, there seems an association between proximity of breast cancer to the skin and the incidence of axillary node positivity or local recurrence. The aim of this study was to determine whether distance of breast cancers from the skin affects the the clinical and pathologic features including the likelihood of axillary nodal metastases, ipsilateral breast cancer recurrence, and recurrence free survival. Methods: Between January 2003 and December 2009, data were collected prospectively regarding 1005 consecutive breast cancer patients who underwent surgical treatment. The exclusion criteria were non-invasive carcinoma (e.g. Ductal Carcinoma In Situ), prior breast surgery, previous radiotherapy or neo-adjuvant chemotherapy and previous endocrine therapy. The distance of the tumor from the skin surface was measured from the skin to the most anterior hypoechoic leading edge of the lesion. Results: A total of 891 patients were included in the statistical analysis, 603(68%) had no axillary nodal metastasis, 288(32%) had axillary nodal metastasis. Distance of breast cancer from the skin less than 3mm induced more axillary nodal metastasis (P = 0.039). However, there was no statistical significant correlation between distance of breast cancer from the skin less than 3mm and ipsilateral breast tumor recurrence (P = 0.788) or recurrence-free survival (P = 0.353). Conclusion: Breast cancers located closer to the skin have a higher incidence of axillary nodal metastasis. When evaluating a breast cancer patient and considering the risk of nodal metastasis the distance of the tumor from the skin should be considered. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-03-01.
Increased Fluorodeoxyglucose Uptake in a Calf Opposite to a Leg With Osteosarcoma After Operation
Authors: HIROFUMI FUJII, SEIEI YASUDA, MICHIRU IDE, WAKOH TAKAHASHI, YUKIHITO MOCHIZUKI, AKIRA SHOHTSU, TADAKI NAKAHARA, ATSUSHI KUBO
Journal: Clinical Nuclear Medicine (2000)

A 19-year-old man with osteosarcoma in the left tibia underwent resection of the primary tumor and partial transplantation of the right fibula to the defect of the left tibia. Although his postoperative course was good, he gradually came to feel fatigue and pain in his right lower leg when he walked. One year later, he underwent fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET). No visible accumulation was noted in the surgically treated left lower leg. But F-18 FDG showed marked accumulation in the right calf muscles. This paradoxical FDG accumulation would explain the easy fatigability and the muscular pain.
Long-Term Marrow Culture Reveals Chromosomally Normal Hematopoietic Progenitor Cells in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
Authors: Laure Coulombel, Dagmar K. Kalousek, Connie J. Eaves, Chander M. Gupta, Allen C. Eaves
Journal: New England Journal of Medicine (1983)

We found that when marrow cells from four patients with newly diagnosed Philadelphia Chromosome-Positive chronic myelogenous leukemia were maintained in culture for two to four weeks, a previously undetectable population of chromosomally normal hematopoietic cells (including erythroid, granulopoietic, and pluripotent progenitors) became readily demonstrable in three cases. Time-course studies showed that in such cultures the dominant Philadelphia Chromosome-Positive population rapidly disappeared, in contrast to coexisting chromosomally normal progenitors, which remained detectable for periods of two to three months. Long-term marrow cultures thus offer a new approach to the assessment of a suppressed but functionally intact population of chromosomally normal hematopoietic stem cells in patients with chronic myelogenous leukemia. (N Engl J Med 1983; 308:1493–8.)
Clinical networks for cancer and cardiac care in England report major funding cuts
Authors: S. Mayor
Journal: BMJ (2012)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Clinical networks for cancer and cardiac care in England report major funding cuts Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Abstract P4-15-03: Patterns of relapse following re-irradiation of the breast using partial breast brachytherapy (PBB)
Authors: M Chadha, K Boachie-Adjei, SK Boolbol, L Kirstein, MP Osborne, P Tarter, LB Harrison
Journal: Cancer Research (2012)

Abstract Purpose: This study is undertaken to evaluate the patterns of relapse among patients with a prior history of irradiation where the RT field included the breast, and who received re-irradiation using PBB for a localized second cancer event in the breast using partial breast. Materials and Methods: Twenty-seven patients were enrolled in an IRB approved study. Nineteen patients had prior history of breast cancer treated with lumpectomy and external beam therapy (ERT), and 8 patients had prior history of mantle RT. All patients underwent lumpectomy with negative margins and received a median dose of 45Gy PBB. The median time interval between the primary breast cancer diagnosis and the second cancer event in the ipsilateral breast is 94-months (range 28-months to 211-months). The median time between mantle RT and the breast cancer is 245 months. Results: At a median follow up of 73 months following lumpectomy and PBB 14.8 % (4/27) patients developed a local recurrence and were salvaged by mastectomy. The 5-year Kaplan Meier local disease-free survival and mastectomy-free survival is 100% and 81%, respectively. Remarkably, one third of patients with prior history of mantle RT developed third primary cancers (pancreas, lung and renal). All patients with the third primary cancers died free of any relapse from the breast cancer. None of the patients with prior history of breast cancer developed a second malignancy, and 3/21 developed distant metastases. Conclusions: In appropriately selected patients with prior history of lumpectomy and ERT for breast cancer we observed a high rate of local control and freedom from mastectomy. Patterns of relapse among patients with prior mantle RT suggest that breast conservation and PBB was appropriate for treating early stage disease. Breast conservation therapy did not have a detrimental effect on breast cancer specific outcome and eventual patient survival. Patients motivated for breast conservation may have an alternative to mastectomy at initial diagnosis. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-15-03.
Intravesical Therapy for Superficial Cancer: Need for More Options
Authors: E. David Crawford
Journal: Journal of Clinical Oncology (2002)

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.15.3185 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12149286 Intravesical Therapy for Superficial Cancer: Need for More Options E. David CrawfordxE. David CrawfordSearch for articles by this author Show More University of Colorado Health Sciences Center, Denver, CO https://doi.org/10.1200/JCO.2002.20.15.3185 Full Text PDF Figures and Tables "Intravesical Therapy for Superficial Cancer: Need for More Options." Journal of Clinical Oncology, 20(15), pp. 3185–3186© 2002 by American Society of Clinical Oncology
PREDICTIVE VALUE OF CHANGES IN SERUM SODIUM IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY
Authors: Jan Griffin, Lisa Wruck, Rachel K. Silverman, Laura Loehr, Stuart Russell, Kunihiro Matsushita, Sunil Agarwal, Anita Deswal, Wayne Rosamond, Patricia Chang
Journal: Journal of the American College of Cardiology (2016)
T cell marker metagene predicts a favourable prognosis in estrogen receptor negative and Her2 positive breast cancers.
Authors: A Rody, E Ruckhaeberle, U Holtrich, R Gaetje, K Engels, L Hanker, C Solbach, A Ahr, D Metzler, T Karn, M Kaufmann
Journal: Cancer Research (2009)

Abstract Abstract #1048 Background: Lymphocyte infiltration (LI) is often seen in breast cancer and has been suggested as a marker of host antitumor immune response but its importance remains controversial. A positive correlation of Her2 amplification/overexpression and LI has been described which was associated with a more favorable outcome. In rapidly proliferating tumors LI is a good prognostic indicator correlating with lymph node negativity, smaller tumor size, lower grade. However the impact of monocytes, B- and T-lymphocytes on prognosis are still a matter of debate.&amp;#x2028; Material and Methods: A database of 2110 primary invasive breast cancer samples from 14 microarray datasets was established. Only Affymetrix HG-U133A microarrays were included for full comparability. Feature reduction was achieved by generating metagenes from genes with strong correlation in unsupervised clustering. The relationship of the five major metagenes with different cell types in the sample as well as differentiation programs/pathways associated with specific expression profiles was analyzed.&amp;#x2028; Results: A large cluster of approximately 600 genes with functions in immune cells was consistently obtained in all datasets. The redundant information from several ProbeSets allowed the construction of robust metagenes which can be used as surrogate markers for the amount of different immune cell types in the breast cancer sample. However, rather complex relationships of these immunological metagenes with standard parameters of the tumors were observed. When different subgroups of tumors were analyzed for disease free survival the IgG metagene as a surrogate marker for B cells had no significant prognostic value. In contrast high expression of the T cell surrogate marker (LCK metagene) was beneficial among all subgroups of ER-negative tumors. Moreover a positive prognostic value of LCK metagene expression was also revealed for those ER-positive tumors with a Her2 overexpression. In addition a trend for a better response to neoadjuvant chemotherapy was detected for those ER negative tumors associated with lymphocyte infiltration as deduced from high expression of both IgG and LCK metagenes.&amp;#x2028; Conclusions: Tumor associated lymphocytes could represent an anti tumor response but on the other hand they might promote tumor progression by shifting the cytokine milieu toward angiogenic factors, inflammatory cytokines and matrix metallo-proteinases. Thus it is crucial to precisely define the specific subtypes of immune cells which are associated with the tumor. Our results demonstrate that this task can be accomplished by a detailed analysis of the expression of metagenes. These surrogate markers define subgroups of tumors with different prognosis. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1048.
Abstract 1568: Plasma-derived circulating microvesicles can both detect and help monitor breast cancer-related pathologies
Authors: Daniel A. Holterman, Janet E. Duncan, Ta Deng, Shannon E. Smith, David B. Spetzler, Christine D. Kuslich
Journal: Cancer Research (2011)

Abstract Circulating microvesicles (cMV) are membrane-bound structures that play an important role in several biologic processes, including angiogenesis and immune modulation. cMV levels are known to change in response to certain pathologies, and specific subpopulations of cMV can be isolated using antibodies targeted to membrane proteins specific for the secreting cells. We examined whether the levels of specific cMV subpopulations are altered in patients with a disease, specifically breast cancer. In order to characterize individual cancer-associated microvesicles (MVs), advanced breast cancer MVs were compared with normal control MVs. Circulating microvesicles were isolated from breast cancer patients or noncancer control patients, stained with fluorochrome-conjugated antibodies, and analyzed using flow cytometry. Tumor-specific antibodies were paired with process-specific markers, such as DLL4 and VEGFR2 for angiogenic cMV, CTLA4 and FasL for immunosuppressive cMV, and CD80 or CD83 for immunostimulatory cMV, to identify and characterize cMV subpopulations. Using this approach, distinct and informative cMV subpopulations were identified and quantified between breast cancer patients and healthy controls. For example, immunosuppressive MVs were elevated in the cancer patients compared with noncancer controls (68% vs 44% of CD45+ cMV coexpressed CTLA4). Additionally, angiogenic MVs were elevated in cancer plasma, with 44% coexpressing DLL4 and CD31 compared with 2% of cMV from noncancer controls. This study suggests that in addition to aiding diagnosis, monitoring specific subpopulations of cMV may offer important information regarding biologic processes perturbed by breast cancer in an individual patient, without the need for an invasive biopsy or a standard pathology evaluation such as immunohistochemistry, and therefore may also aid in prognosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1568. doi:10.1158/1538-7445.AM2011-1568
SP0179 Biological Changes in Early Systemic Sclerosis
Authors: S. Vettori
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Early systemic sclerosis (SSc) is a newly identified condition characterized by the association of Raynaud9s phenomenon (RP) with SSc marker autoantibodies and/or with a scleroderma pattern at nailfold videocapillaroscopy (NVC), without clinical manifestations of definite SSc. Patients with early SSc do not meet the old 1980 American College of Rheumatology (ACR) nor the new 2013ACR/European League Against Rheumatism (EULAR) classification criteria for the disease. Nevertheless, they show a scleroderma-type preclinical involvement of internal organs at second level examinations in up to 42% of cases and increased serum levels of markers of endothelial, T-cell, and fibroblast activation. A number of these circulating markers, like sICAM-1, CCL2, CXCL8, and IL-13 increase their serum levels in parallel with the onset and the extent of skin sclerosis. They have been found to be elevated in patients with early SSc, but reach the highest levels in definite SSc patients with a diffuse skin disease. Other circulating markers display a peculiar behavior, being associated with distinct early SSc subsets. In fact, the carboxyterminal telopeptide of type I collagen (ICTP) has been found to be higher in early SSc patients with marker autoantibodies and impaired DLCO, while sE-selectin has been found to be higher in early SSc patients with an NVC scleroderma pattern and puffy fingers. More interestingly, IL-33, an inflammatory cytokine belonging to the IL-1β superfamily enriched in epithelial and endothelial cells, has been found to be higher in patient with early SSc than in patients with a definite, classifiable disease. Taken together, these data suggest that the cellular pathways that are implicated in the complex vascular/immune pathogenesis of SSc are active in patients with an early pre-fibrotic stage of the disease, when an increased collagen synthesis can also be suspected. In addition, they suggest that serum levels of some adhesion molecules, chemokines and cytokines may be helpful to follow the evolution of early SSc into definite SSc, while IL-33 may be investigated in large patient series as a potential biomarker of the early subset. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6230
Dietary Fat and the Risk of Breast Cancer
Authors: Walter C. Willett, Meir J. Stampfer, Graham A. Colditz, Bernard A. Rosner, Charles H. Hennekens, Frank E. Speizer
Journal: New England Journal of Medicine (1987)

Dietary fat has been suggested as a risk factor for breast cancer in women, but the available data on humans are sparse and inconsistent. In 1980, 89,538 U.S. registered nurses who were 34 to 59 years of age and had no history of cancer completed a previously validated dietary questionnaire designed to measure individual consumption of total fat, saturated fat, linoleic acid, and cholesterol, as well as other nutrients. In a subsample of 173 participants studied in detail, those in the highest quintile of fat intake consumed a mean of 44 percent of calories from fat, as compared with 32 percent for those in the lowest quintile. During four years of follow-up, 601 cases of breast cancer were diagnosed among the 89,538 nurses in the study. After adjustment for known determinants in multivariate analyses, the relative risk of breast cancer among women in the highest quintile of calorie-adjusted total fat intake, as compared with women in the lowest quintile, was 0.82 (95 percent confidence limits, 0.64 and 1.05). The corresponding relative risks were 0.84 (confidence limits, 0.66 and 1.08) for saturated fat, 0.88 (0.69 and 1.12) for linoleic acid, and 0.91 (0.70 and 1.18) for cholesterol intake. Similar results were found for both postmenopausal and premenopausal women. These data are based on a limited period of follow-up and do not exclude a possible influence of fat intake before adulthood or at levels lower than 30 percent of calories. They suggest, however, that a moderate reduction in fat intake by adult women is unlikely to result in a substantial reduction in the incidence of breast cancer. (N Engl J Med 1987;316:22–8.)
Band ligation of a T1 esophageal squamous cell cancer in a patient with multimorbidities
Authors: S. Salord, J. Gornals, M. Galan, J. Botargues, J. Castellví, M. Miró
Journal: Endoscopy (2012)

Endoscopic band ligation without resection is a technique reported in the literature for the treatment of subepithelial neuroendocrine tumors and Barrett's esophagus, but its use in the treatment of T1 cancer has not been reported [1] [2] [3] [4]. We present a case of T1 esophageal cancer in a patient with contraindications for surgery treated endoscopically using banding without resection.
Europe Grapples With Funding for Research
Authors: C. Vanchieri
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Europe Grapples With Funding for Research Get access Cori Vanchieri Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 16, August 1993, Page 1276, https://doi.org/10.1093/jnci/85.16.1276 Published: 01 August 1993
RESULTADO DE UN SEGUNDO INTENTO DE CPRE EN PACIENTES CON PREVIA CANULACIÓN FALLIDA Y PRECORTE DE LA PAPILA
Authors: A Aldana Grisales, C Leal, D Royg, A Fernández-Simon, O Sendino, JM Bordas, J Llach, A Cárdenas
Journal: Endoscopy (2013)

Introducción: La CPRE es una prueba rutinaria que se realiza en pacientes con diversas patologías de la vía biliar. Sin embargo hay un 5 – 10% de pacientes en los cuales no se puede canular profundamente la vía biliar con cánulas o esfinterótomos estándares. Aunque el precorte de la papila con bisturí o esfinterótomo incrementa el éxito de canulación, en algunos pacientes este método falla. Objetivo: Determinar la tasa de éxito de canulación profunda de la vía biliar en un segundo intento de CPRE, cuyo primer intento ha sido fallido y se ha realizado un precorte de la papila. Material y Método: Análisis retrospectivo de pacientes con CPRE fallida a quienes se les realizó precorte de la papila entre 2006 – 2013 y luego se re-intentó canular la vía biliar un segundo tiempo. Resultados: Se analizaron un total de 59 pacientes y se accedió con éxito a la vía biliar en 44 (75%). A 42, se les realizó algún tipo de procedimiento terapéutico, que en todos los casos fue considerado exitoso. Las variables estadísticamente relacionadas con el éxito de canulación fueron: la edad < 80 años, el tiempo de realización de la segunda prueba entre 4 – 7 días, y la ausencia de divertículo duodenal. La incidencia de complicaciones en la cohorte de pacientes en el primer intento fue del 5% y en el segundo intento fue del 8%. Conclusiones: La realización de un segundo intento de CPRE en pacientes con canulacion fallida y precorte en la prueba índice es una técnica eficaz y segura y por lo tanto se amerita repetir la prueba en el lapso de unos 4 – 7 días. Sin embargo se necesitan estudios prospectivos y con mayor número de pacientes para confirmar estos Resultados: